Current standards suggest that for high-risk patients, extending therapy to a decade can further decrease the risk of late recurrence
However, they shared this statement to SELF: Semaglutides efficacy and safety have been extensively demonstrated in people with obesity/overweight with robust evidence for improving health outcomes
doi: 10.1007/s00726-012-1361-4 38 LiuZXiaYZhangXLiuLTuSZhuWet al
Clinical studies have found tirzepatide to result in more weight loss than semaglutide, which is the active ingredient in Ozempic and Wegovy
As the cornerstone of the skin's integrity, it promotes elasticity, support, and hydration, resulting in a youthful and smooth appearance
The compounding question is narrower and more unsettled because FDA has evaluated or listed related bulk substances due to safety and characterization concerns